Fact.MR, a market research and competitive intelligence provider, has conducted a comprehensive analysis on the pulmonary arterial hypertension (PAH) market, which is expected to rise at a CAGR of 5.4% over the forecast period (2021 to 2028).
Pulmonary arterial hypertension is a severe pulmonary arterial hypertension illness. With the rising incidences of heart problems, which lead to pulmonary arterial hypertension, the market is predicted to develop significantly over the forecast period.
Recent advances in the treatment of pulmonary arterial hypertension have resulted in improved clinical results, including a lower death rate and a higher quality of life. The market is expected to be driven by an increase in the number of drug pipelines and rising healthcare spending in various areas of the world. Demand will also increase as the senior population grows and the global prevalence of hypertension rises.
In addition, ongoing research targeted at producing highly specific and effective therapeutics for PAH is focusing on developing integrative medicines that combine traditional and experimental substances.
Key Takeaways from Market Study
- Global pulmonary arterial hypertension market to reach a valuation of US$ 4.44 Bn by 2028.
- Market in North America holds a share of 35%.
- Demand for endothelin receptor antagonists (ERAs) is expected to increase at a 5% CAGR over the forecast period.
“Governments from all over the world are providing funds for the research and provision of high-quality treatments for pulmonary arterial hypertension; this key factor will stimulate market expansion over the coming years,” says a Fact.MR analyst
Request Sample Report
Various strategic efforts are being implemented by industry participants in order to expand their market share. Product development and launches, distribution network expansion, partnerships, and mergers and acquisitions are all examples of this. To obtain a competitive advantage and strengthen their industrial presence, companies invest extensively in the development and sale of highly innovative products.
Many pharmaceutical companies are attempting to enter the PAH market by releasing generic versions of pulmonary arterial hypertension medications. In the next years, this is expected to boost competition.
- In November 2020, Viatris Inc. was formed by combining Mylan N.V. and Pfizer Inc.’s Upjohn Business. Viatris has a large portfolio of biosimilars, branded and sophisticated generics, and over-the-counter pharmaceuticals, including Revatio, a PAH medication.
More Valuable Insights on Offer
Fact.MR, in its new offering, presents an unbiased analysis of the global pulmonary arterial hypertension market, presenting historical demand data (2017-2020) and forecast statistics for the period of 2021-2028.
The study divulges essential insights on the market on the basis of drug class (prostacyclin & prostacyclin analogs, endothelin receptor antagonists (ERAs), phosphodiesterase-5 (PDE-5) inhibitors, and soluble guanylate cyclase (sGC) stimulators), by pipeline analysis (early-stage drug candidates (phase I & phase II) and late-stage drug candidates (phase III & registration Phase)), across five major regions (North America, Europe, Asia Pacific, Latin America, and MEA).
Fact.MR’s Domain Knowledge in Healthcare
Our healthcare consulting team guides organizations at each step of their business strategy by helping you understand how the latest influencers account for operational and strategic transformation in the healthcare sector. Our expertise in recognizing the challenges and trends impacting the global healthcare industry provides indispensable insights and support – encasing a strategic perspective that helps you identify critical issues and devise appropriate solutions.
For more information, refer to our market research report or contact the PR author.